TY - JOUR
T1 - Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis
AU - Michelsen, Brigitte
AU - Ørnbjerg, Lykke Midtbøll
AU - Kvien, Tore K
AU - Pavelka, Karel
AU - Nissen, Michael J
AU - Nordström, Dan
AU - Santos, Maria José
AU - Koca, Suleyman Serdar
AU - Askling, Johan
AU - Rotar, Ziga
AU - Gudbjornsson, Bjorn
AU - Codreanu, Catalin
AU - Loft, Anne Gitte
AU - Kristianslund, Eirik Klami
AU - Mann, Herman F
AU - Ciurea, Adrian
AU - Eklund, Kari K
AU - Vieira-Sousa, Elsa
AU - Yazici, Ayten
AU - Jacobsson, Lennart
AU - Tomšič, Matija
AU - Löve, Thorvardur Jón
AU - Ionescu, Ruxandra
AU - van der Horst-Bruinsma, I E
AU - Iannone, Florenzo
AU - Pombo-Suarez, Manuel
AU - Jones, Gareth T
AU - Hyldstrup, Lise Hejl
AU - Krogh, Niels Steen
AU - Hetland, Merete Lund
AU - Østergaard, Mikkel
N1 - COPECARE
PY - 2020/9/1
Y1 - 2020/9/1
N2 - OBJECTIVES: To assess the impact of 'patient's minus evaluator's global assessment of disease activity' (ΔPEG) at treatment initiation on retention and remission rates of TNF inhibitors (TNFi) in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients across Europe.METHODS: Real-life data from PsA and axSpA patients starting their first TNFi from 11 countries in the European Spondyloarthritis Research Collaboration Network were pooled. Retention rates were compared by Kaplan-Meier analyses with log-rank test and by Cox regression, and remission rates by χ2 test and by logistic regression across quartiles of baseline ΔPEG, separately in female and male PsA and axSpA patients.RESULTS: We included 14 868 spondyloarthritis (5855 PsA, 9013 axSpA) patients. Baseline ΔPEG was negatively associated with 6/12/24-months' TNFi retention rates in female and male PsA and axSpA patients (P <0.001), with 6/12/24-months' BASDAI < 2 (P ≤0.002) and ASDAS < 1.3 (P ≤0.005) in axSpA patients, and with DAS28CRP(4)<2.6 (P ≤0.04) and DAPSA28 ≤ 4 (P ≤0.01), but not DAS28CRP(3)<2.6 (P ≥0.13) in PsA patients, with few exceptions on remission rates. Retention and remission rates were overall lower in female than male patients.CONCLUSION: High baseline patient's compared with evaluator's global assessment was associated with lower 6/12/24-months' remission as well as retention rates of first TNFi in both PsA and axSpA patients. These results highlight the importance of discordance between patient's and evaluator's perspective on disease outcomes.
AB - OBJECTIVES: To assess the impact of 'patient's minus evaluator's global assessment of disease activity' (ΔPEG) at treatment initiation on retention and remission rates of TNF inhibitors (TNFi) in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients across Europe.METHODS: Real-life data from PsA and axSpA patients starting their first TNFi from 11 countries in the European Spondyloarthritis Research Collaboration Network were pooled. Retention rates were compared by Kaplan-Meier analyses with log-rank test and by Cox regression, and remission rates by χ2 test and by logistic regression across quartiles of baseline ΔPEG, separately in female and male PsA and axSpA patients.RESULTS: We included 14 868 spondyloarthritis (5855 PsA, 9013 axSpA) patients. Baseline ΔPEG was negatively associated with 6/12/24-months' TNFi retention rates in female and male PsA and axSpA patients (P <0.001), with 6/12/24-months' BASDAI < 2 (P ≤0.002) and ASDAS < 1.3 (P ≤0.005) in axSpA patients, and with DAS28CRP(4)<2.6 (P ≤0.04) and DAPSA28 ≤ 4 (P ≤0.01), but not DAS28CRP(3)<2.6 (P ≥0.13) in PsA patients, with few exceptions on remission rates. Retention and remission rates were overall lower in female than male patients.CONCLUSION: High baseline patient's compared with evaluator's global assessment was associated with lower 6/12/24-months' remission as well as retention rates of first TNFi in both PsA and axSpA patients. These results highlight the importance of discordance between patient's and evaluator's perspective on disease outcomes.
KW - axial spondyloarthritis
KW - psoriatic arthritis
KW - TNF inhibitors
KW - treatment outcomes
UR - http://www.scopus.com/inward/record.url?scp=85090080184&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kez656
DO - 10.1093/rheumatology/kez656
M3 - Journal article
C2 - 31960053
SN - 1462-0324
VL - 59
SP - 2455
EP - 2461
JO - Rheumatology (Oxford, England)
JF - Rheumatology (Oxford, England)
IS - 9
ER -